Sevasemten Dose 2

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)NCT05540860EWTXPhase 2Active not recruiting2027-01Estimated
Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene TherapyNCT06100887EWTXPhase 2Active not recruiting2027-03Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.